Clinical trials
High Grade Glioma (III or IV) clinical trials
Below are recruiting high grade glioma (iii or iv) clinical trials, each written for real people, not researchers. We’re tracking 1,259 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT04467723RecruitingPhase 1/Phase 2
Atezolizumab plus pirfenidone for advanced lung cancer
This Phase 1/2 trial tests whether combining atezolizumab and pirfenidone can help people with non-small cell lung cancer (NSCLC) after prior treatment. It is aimed at patients whose cancer has certain genetic markers ruled out and who can safely take study medicines and follow frequent visits.
Fairway, KansasAges 18 years+ - NCT04444362Enrolling by invitation
Probacine to protect organs after cardiovascular surgery
This study tests whether a medicine called Probacine can help protect your gut and organs after cardiovascular surgery. If you qualify, you may be asked to take part and follow the study plan to see if complications are reduced.
Beijing, Beijing MunicipalityAges 18–90 - NCT04381936RecruitingPhase 3
Testing COVID-19 or pneumonia treatments in hospitalized patients
This trial tests different treatments for serious lung infections in people who are already in the hospital. It may help doctors learn which treatment works best for recovery and survival when pneumonia-like illness is suspected.
BrusselsAges birth+ - NCT04416581RecruitingPhase 4
Compare two stomach-protecting medicines to prevent bleeding
This trial compares a potassium-competitive acid blocker to a proton pump inhibitor to help prevent stomach or intestinal bleeding in people at high risk who take blood-thinning medicines. It may help reduce dangerous GI bleeding while you stay on heart/stroke medicines.
AnyangAges 19 years+ - NCT04323748RecruitingPhase 1
Testing a stronger rituximab dose schedule for new ITP
This trial studies whether a “dose-dense” rituximab schedule can help children and teens with newly diagnosed, high-risk immune thrombocytopenia (ITP). It aims to raise/maintain platelet counts and control bleeding, while carefully checking safety.
Vahalla, New YorkAges 1–21 - NCT04329065RecruitingPhase 2
Vaccine with targeted breast cancer drugs before surgery
This Phase 2 trial tests whether adding a cancer vaccine (with GM-CSF) to standard HER2-targeted chemotherapy before surgery improves treatment outcomes for HER2-positive breast cancer. If you join, you’ll receive planned medicine before surgery to treat the tumor, then continue with the study schedule.
Seattle, WashingtonAges 18 years+ - NCT04172532RecruitingPhase 1/Phase 2
New targeted drug with radiation for locally advanced pancreatic cancer
This Phase 1/2 trial tests adding peposertib, a targeted anti-cancer drug, to standard radiation for people with locally advanced pancreatic adenocarcinoma. It aims to improve control of the cancer after initial chemotherapy and determine whether the combo is safe and effective.
Duarte, CaliforniaAges 18 years+ - NCT04181060RecruitingPhase 3
Osimertinib alone or with bevacizumab for EGFR-mutant lung cancer
This Phase 3 trial tests whether starting osimertinib with or without bevacizumab helps people with advanced EGFR-mutant lung cancer live longer and control the cancer better. Your EGFR mutation test result and past treatments are key to whether you can join.
Anchorage, AlaskaAges 18 years+ - NCT04169763RecruitingPhase 1
Nelfinavir with chemo and radiation for vulvar cancer
This Phase 1 trial tests whether adding nelfinavir to standard chemo (cisplatin) and external-beam radiation can treat locally advanced vulvar cancer that cannot be removed with surgery. It’s designed to check safety and how well the treatment can work for this situation.
Houston, TexasAges 18 years+ - NCT04237701Recruiting
Tracking heart failure in real time at Yale
This trial looks at how people with heart failure are doing using real-time monitoring across the Yale New Haven Health System. It may help improve care by spotting problems sooner and tracking treatment effects.
New Haven, ConnecticutAges 18 years+ - NCT04165070RecruitingPhase 1/Phase 2
Stage IV lung cancer trial using pembrolizumab with or without chemotherapy
This Phase 1/2 study tests pembrolizumab (an immune-based cancer treatment) either alone or with chemotherapy in people newly diagnosed with stage IV non-small cell lung cancer (NSCLC). It looks at how well the treatments work and whether they are safe, especially in people who haven’t had treatment yet for metastatic disease.
Gilbert, ArizonaAges 18 years+ - NCT01937949Recruiting
Fenestrated stent treatment for complex abdominal aortic aneurysms
This trial studies a custom-made stent graft placed from inside the blood vessel to treat complex aneurysms in the aorta. It may help prevent rupture and manage aneurysm risk, but it requires specific aneurysm anatomy and follow-up.
Rochester, MinnesotaAges 18 years+ - NCT04031677RecruitingPhase 3
Surgery with or without chemotherapy for high-risk retroperitoneal sarcoma
This trial studies whether adding chemotherapy before surgery helps people with high-risk retroperitoneal (abdominal-area) leiomyosarcoma or liposarcoma. The goal is to improve outcomes while comparing surgery alone versus surgery plus neoadjuvant chemotherapy.
Birmingham, AlabamaAges 18 years+ - NCT04114136RecruitingPhase 2
Study tests pembrolizumab or nivolumab plus a diabetes-like drug
This Phase 2 study tests whether adding a metabolic (diabetes-related) medicine to an immune therapy (pembrolizumab or nivolumab) can better control certain solid tumors. It may help people whose standard treatment would usually be pembrolizumab or nivolumab alone.
Pittsburgh, PennsylvaniaAges 18 years+ - NCT04105270RecruitingPhase 2
Durvalumab plus chemo with RMT for lung cancer
This Phase 2 trial studies a new treatment plan that combines RMT with durvalumab and chemotherapy in people with untreated advanced lung adenocarcinoma. It aims to improve outcomes by helping the immune system and fighting cancer cells together.
Phoenix, ArizonaAges 18 years+ - NCT03959085RecruitingPhase 3
Inotuzumab plus chemotherapy for high-risk childhood leukemia
This Phase 3 trial tests whether adding inotuzumab to standard post-induction chemotherapy improves outcomes for children and young teens with high-risk B-ALL, mixed phenotype acute leukemia (MPAL), or certain high-risk B-LLy. It may help by targeting leukemia cells more directly, but participation depends on specific age, lab results, and medical history rules.
Birmingham, AlabamaAges 12 months–25 years - NCT03937635RecruitingPhase 3
Lenalidomide and dexamethasone, with or without daratumumab
This phase 3 trial studies whether lenalidomide plus dexamethasone can prevent or delay progression of “high-risk smoldering” multiple myeloma, and whether adding daratumumab improves outcomes. It’s meant for people who are not yet showing symptoms, but whose lab and scan results suggest higher risk.
Birmingham, AlabamaAges 18 years+ - NCT03826433RecruitingPhase 1
Study stem cell treatment for worsening hepatitis B cirrhosis
This Phase 1 study tests a stem cell product to see if it is safe and how it affects people with worsening hepatitis B-related cirrhosis. It may help researchers understand whether the treatment could improve liver function in this stage of illness.
Changsha, HunanAges 18–60 - NCT03804944RecruitingPhase 2
Vaccine trial for hormone-positive breast cancer
This Phase 2 study tests an individualized vaccine made from your tumor information to help your immune system fight hormone-positive breast cancer. You may be able to participate if you meet specific hormone-receptor, health, and treatment-timing requirements.
Los Angeles, CaliforniaAges 18–90 - NCT03678025RecruitingPhase 3
Standard treatment for metastatic prostate cancer, with or without local treatment
This Phase 3 trial studies whether using the usual medicines for metastatic prostate cancer, plus a definitive local treatment to the prostate, improves outcomes. It may help determine if treating the prostate directly can benefit people whose cancer has not worsened after initial hormone-based treatment.
Gilbert, ArizonaAges 18 years+ - NCT03606967RecruitingPhase 2
Individualized vaccine added to standard treatment for metastatic triple-negative breast cancer
This Phase 2 trial tests whether adding a personalized cancer vaccine to durvalumab (an immunotherapy), tremelimumab (another immunotherapy), and chemotherapy can improve outcomes for people with metastatic triple-negative breast cancer. It may help your immune system recognize your specific tumor features.
Orange, CaliforniaAges 18 years+ - NCT03594760RecruitingPhase 3
PSMA PET scan study using advanced computer imaging in prostate cancer
This Phase 3 study looks at how a PSMA PET scan can predict how prostate cancer will progress and how well treatment is working. If your doctor at CHUM orders this scan, you may be able to join to help refine better predictions for future patients.
Montreal, QuebecAges 18 years+ - NCT03608631RecruitingPhase 1/Phase 2
Exosome treatment for KRAS-mutated metastatic pancreatic cancer
This Phase 1/2 study tests an investigational treatment made from “exosomes” for people with metastatic pancreatic cancer that has a specific KRAS mutation (KRAS G12D). It aims to see if this treatment can control the cancer and is safe for patients whose cancer has grown or stayed the same after prior chemotherapy.
Houston, TexasAges 18 years+ - NCT03694236RecruitingPhase 1/Phase 2
Durvalumab with chemoradiation before lung tumor surgery
This trial studies whether adding durvalumab (an immune therapy) to standard chemoradiation before surgery can improve outcomes for people with stage III, resectable lung cancer. It aims to help shrink the tumor and improve chances of successful treatment.
Seoul, SeoulAges 20 years+
Hear when a new High Grade Glioma (III or IV) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for high grade glioma (iii or iv)?
- Yes. Clin2 currently lists 1,259 recruiting high grade glioma (iii or iv) studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a high grade glioma (iii or iv) trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a high grade glioma (iii or iv) trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.